These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2902131)

  • 21. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease.
    Snydman DR
    Rev Infect Dis; 1990; 12 Suppl 7():S839-48. PubMed ID: 2173113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytomegalovirus hyperimmune globulin prophylaxis in bone marrow transplants in children with various diseases].
    Ebell W; Blütters-Sawatzki R; Friedrich W; Hampl W; Kleihauer E
    Immun Infekt; 1985 Nov; 13(6):307-12. PubMed ID: 3000925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation.
    Pollard RB
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S97-102. PubMed ID: 2456512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J; Ross H; Bara C; Delgado JF; Dengler T; Lehmkuhl HB; Wang SS; Dong G; Witte S; Junge G; Potena L
    Transpl Infect Dis; 2013 Apr; 15(2):150-62. PubMed ID: 23013440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
    Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
    J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is routine post-operative surveillance for cytomegalovirus infection following heart transplantation necessary?
    Madden BP; Reynolds L; Tryhorn Y; Booth J; Backhouse L; Murday A
    Eur J Cardiothorac Surg; 1998 Jul; 14(1):15-7; discussion 17-8. PubMed ID: 9726609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin prophylaxis of cytomegalovirus infection in pediatric renal transplant recipients.
    Flynn JT; Kaiser BA; Long SS; Schulman SL; Deforest A; Polinsky MS; Baluarte HJ
    Am J Nephrol; 1997; 17(2):146-52. PubMed ID: 9096445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Merigan TC; Renlund DG; Keay S; Bristow MR; Starnes V; O'Connell JB; Resta S; Dunn D; Gamberg P; Ratkovec RM
    N Engl J Med; 1992 Apr; 326(18):1182-6. PubMed ID: 1313549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Frequency of infection with cytomegaloviruses (CMV) following kidney transplantation and initial experiences with CMV gamma globulin prevention].
    Kaden J; Scholz D; Eichler C; May G
    Immun Infekt; 1985 Nov; 13(6):290-5. PubMed ID: 3000922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection.
    Steinmuller DR; Novick AC; Streem SB; Graneto D; Swift C
    Transplantation; 1990 Jan; 49(1):68-70. PubMed ID: 2154068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
    Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
    Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Modification of the incidence and course of CMV infections following kidney transplantation by passive immunization--initial experiences with a hyperimmunoglobulin].
    Hoyer J; Dennin RH; Schulz E
    Immun Infekt; 1985 Nov; 13(6):285-9. PubMed ID: 3000921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy.
    Mendez-Eirin E; Paniagua-Martín MJ; Marzoa-Rivas R; Barge-Caballero E; Grille-Cancela Z; Cañizares A; Naya-Leira C; Gargallo-Fernández P; Castro-Beiras A; Crespo-Leiro M
    Transplant Proc; 2012 Nov; 44(9):2660-2. PubMed ID: 23146486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.